106 related articles for article (PubMed ID: 32862619)
21. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
22. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
24. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
[TBL] [Abstract][Full Text] [Related]
25. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
27. Gamma-glutamyltransferase as a preoperative differential diagnostic marker in patients with adnexal mass.
Reiser E; Aust S; Seebacher V; Reinthaller A; von Mersi H; Schwameis R; Polterauer S; Grimm C; Helmy-Bader S
Eur J Obstet Gynecol Reprod Biol; 2019 Aug; 239():16-20. PubMed ID: 31158789
[TBL] [Abstract][Full Text] [Related]
28. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.
Ruggeri G; Bandiera E; Zanotti L; Belloli S; Ravaggi A; Romani C; Bignotti E; Tassi RA; Tognon G; Galli C; Caimi L; Pecorelli S
Clin Chim Acta; 2011 Jul; 412(15-16):1447-53. PubMed ID: 21557935
[TBL] [Abstract][Full Text] [Related]
29. Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.
Lokich E; Palisoul M; Romano N; Craig Miller M; Robison K; Stuckey A; DiSilvestro P; Mathews C; Granai CO; Lambert-Messerlian G; Moore RG
Gynecol Oncol; 2015 Nov; 139(2):248-52. PubMed ID: 26364809
[TBL] [Abstract][Full Text] [Related]
30. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
[TBL] [Abstract][Full Text] [Related]
31. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
Yoshida A; Derchain SF; Pitta DR; Andrade LA; Sarian LO
Gynecol Oncol; 2016 Mar; 140(3):481-5. PubMed ID: 26825617
[TBL] [Abstract][Full Text] [Related]
32. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.
Timmerman D; Van Calster B; Testa A; Savelli L; Fischerova D; Froyman W; Wynants L; Van Holsbeke C; Epstein E; Franchi D; Kaijser J; Czekierdowski A; Guerriero S; Fruscio R; Leone FPG; Rossi A; Landolfo C; Vergote I; Bourne T; Valentin L
Am J Obstet Gynecol; 2016 Apr; 214(4):424-437. PubMed ID: 26800772
[TBL] [Abstract][Full Text] [Related]
33. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
34. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
35. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
[TBL] [Abstract][Full Text] [Related]
36. Comparative evaluation of the risk of malignancy index scoring systems (1-4) used in differential diagnosis of adnexal masses.
Ozbay PO; Ekinci T; Caltekin MD; Yilmaz HT; Temur M; Yilmaz O; Uysal S; Demirel E; Kelekci S
Asian Pac J Cancer Prev; 2015; 16(1):345-9. PubMed ID: 25640377
[TBL] [Abstract][Full Text] [Related]
37. Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
Chudecka-Głaz A; Cymbaluk-Płoska A; Jastrzębska J; Menkiszak J
Tumour Biol; 2016 Jul; 37(7):8879-87. PubMed ID: 26753953
[TBL] [Abstract][Full Text] [Related]
38. Utilization of ultrasound as a diagnostic tool in the preoperative assessment of patients with adnexal masses.
Terzic M; Dotlic J; Bila J; Pilic I; Nikolic B; Kocijancic D; Likic I; Arsenovic N; Mihailovic T; Bugarski D
J BUON; 2015; 20(3):862-9. PubMed ID: 26214641
[TBL] [Abstract][Full Text] [Related]
39. [Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F 18 fluorodeoxyglucose].
Fenchel S; Kotzerke J; Stöhr I; Grab D; Nüssle K; Rieber A; Kreienberg R; Brambs HJ; Reske SN
Nuklearmedizin; 1999; 38(4):101-7. PubMed ID: 10392374
[TBL] [Abstract][Full Text] [Related]
40. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
